AlphaCore Capital LLC grew its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 364.6% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,626 shares of the medical research company's stock after acquiring an additional 1,276 shares during the period. AlphaCore Capital LLC's holdings in Thermo Fisher Scientific were worth $846,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently modified their holdings of TMO. Forum Financial Management LP grew its holdings in Thermo Fisher Scientific by 45.0% during the fourth quarter. Forum Financial Management LP now owns 3,192 shares of the medical research company's stock valued at $1,661,000 after purchasing an additional 991 shares during the period. Baer Investment Advisory LLC bought a new position in shares of Thermo Fisher Scientific during the 4th quarter worth $799,000. Wormser Freres Gestion boosted its position in Thermo Fisher Scientific by 1.5% during the fourth quarter. Wormser Freres Gestion now owns 14,953 shares of the medical research company's stock worth $7,841,000 after purchasing an additional 222 shares during the period. Warm Springs Advisors Inc. bought a new position in Thermo Fisher Scientific during the fourth quarter worth about $2,051,000. Finally, North Star Asset Management Inc. boosted its position in Thermo Fisher Scientific by 2.9% during the fourth quarter. North Star Asset Management Inc. now owns 55,625 shares of the medical research company's stock worth $28,938,000 after purchasing an additional 1,581 shares during the period. 89.23% of the stock is owned by institutional investors.
Thermo Fisher Scientific Trading Down 0.4%
Thermo Fisher Scientific stock traded down $1.67 during mid-day trading on Wednesday, hitting $401.88. The company's stock had a trading volume of 1,930,021 shares, compared to its average volume of 1,872,985. Thermo Fisher Scientific Inc. has a 12 month low of $390.50 and a 12 month high of $627.88. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The business has a 50 day moving average price of $437.74 and a 200-day moving average price of $502.70. The stock has a market cap of $151.71 billion, a price-to-earnings ratio of 24.31, a price-to-earnings-growth ratio of 2.99 and a beta of 0.82.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The firm had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. During the same quarter in the previous year, the company posted $5.11 earnings per share. The business's revenue was up .2% on a year-over-year basis. As a group, analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.
Thermo Fisher Scientific Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.43%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific's dividend payout ratio (DPR) is 10.09%.
Analysts Set New Price Targets
Several research firms recently commented on TMO. Raymond James reaffirmed an "outperform" rating and issued a $667.00 price objective (up from $650.00) on shares of Thermo Fisher Scientific in a report on Monday, February 3rd. Stifel Nicolaus cut their price target on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a report on Thursday, April 24th. Royal Bank of Canada cut their target price on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a research note on Thursday, April 24th. Robert W. Baird cut their target price on Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating for the company in a research note on Thursday, April 24th. Finally, Barclays cut their price objective on shares of Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating for the company in a research report on Thursday, April 10th. Four analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, Thermo Fisher Scientific has an average rating of "Moderate Buy" and a consensus target price of $607.43.
Read Our Latest Stock Analysis on Thermo Fisher Scientific
Insider Buying and Selling at Thermo Fisher Scientific
In related news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the transaction, the executive vice president now directly owns 23,167 shares of the company's stock, valued at $9,960,188.31. This represents a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Michael A. Boxer sold 3,775 shares of the stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the completion of the transaction, the senior vice president now directly owns 10,816 shares of the company's stock, valued at approximately $5,759,736.32. The trade was a 25.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 14,075 shares of company stock valued at $7,305,942 in the last 90 days. Insiders own 0.33% of the company's stock.
Thermo Fisher Scientific Company Profile
(
Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
See Also
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
